472 related articles for article (PubMed ID: 14996430)
1. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures.
Valente EG; Vernet D; Ferrini MG; Qian A; Rajfer J; Gonzalez-Cadavid NF
Nitric Oxide; 2003 Dec; 9(4):229-44. PubMed ID: 14996430
[TBL] [Abstract][Full Text] [Related]
2. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model.
Vernet D; Ferrini MG; Valente EG; Magee TR; Bou-Gharios G; Rajfer J; Gonzalez-Cadavid NF
Nitric Oxide; 2002 Dec; 7(4):262-76. PubMed ID: 12446175
[TBL] [Abstract][Full Text] [Related]
3. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease.
Davila HH; Ferrini MG; Rajfer J; Gonzalez-Cadavid NF
BJU Int; 2003 Jun; 91(9):830-8. PubMed ID: 12780843
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease.
Ferrini MG; Kovanecz I; Nolazco G; Rajfer J; Gonzalez-Cadavid NF
BJU Int; 2006 Mar; 97(3):625-33. PubMed ID: 16469038
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.
Gonzalez-Cadavid NF; Rajfer J
Nat Rev Urol; 2010 Apr; 7(4):215-21. PubMed ID: 20212516
[TBL] [Abstract][Full Text] [Related]
6. Antifibrotic role of inducible nitric oxide synthase.
Ferrini MG; Vernet D; Magee TR; Shahed A; Qian A; Rajfer J; Gonzalez-Cadavid NF
Nitric Oxide; 2002 May; 6(3):283-94. PubMed ID: 12009846
[TBL] [Abstract][Full Text] [Related]
7. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat.
Ferrini MG; Kovanecz I; Sanchez S; Vernet D; Davila HH; Rajfer J; Gonzalez-Cadavid NF
Biol Reprod; 2007 May; 76(5):915-23. PubMed ID: 17287493
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of nitric oxide synthase and arginase in the induction of a Peyronie's-like condition in the rat.
Bivalacqua TJ; Champion HC; Leungwattanakij S; Yang DY; Hyun JS; Abdel-Mageed AB; Sikka SC; Kadowitz PJ; Hellstrom WJ
J Androl; 2001; 22(3):497-506. PubMed ID: 11330651
[TBL] [Abstract][Full Text] [Related]
9. Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie's disease.
Davila HH; Magee TR; Vernet D; Rajfer J; Gonzalez-Cadavid NF
Biol Reprod; 2004 Nov; 71(5):1568-77. PubMed ID: 15240426
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling.
Das A; Xi L; Kukreja RC
J Biol Chem; 2005 Apr; 280(13):12944-55. PubMed ID: 15668244
[TBL] [Abstract][Full Text] [Related]
11. The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets.
Gelfand RA; Vernet D; Kovanecz I; Rajfer J; Gonzalez-Cadavid NF
J Sex Med; 2015 Feb; 12(2):313-27. PubMed ID: 25496134
[TBL] [Abstract][Full Text] [Related]
12. Chronic inhibition of nitric-oxide synthase induces hypertension and erectile dysfunction in the rat that is not reversed by sildenafil.
Gur S; Kadowitz PJ; Gurkan L; Chandra S; Dewitt SY; Harbin A; Sikka SC; Agrawal KC; Hellstrom WJ
BJU Int; 2010 Jul; 106(1):78-83. PubMed ID: 20002674
[TBL] [Abstract][Full Text] [Related]
13. Experimental models of Peyronie's disease. Implications for new therapies.
Gonzalez-Cadavid NF; Rajfer J
J Sex Med; 2009 Feb; 6(2):303-13. PubMed ID: 19138365
[TBL] [Abstract][Full Text] [Related]
14. Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models.
Ilg MM; Mateus M; Stebbeds WJ; Milenkovic U; Christopher N; Muneer A; Albersen M; Ralph DJ; Cellek S
Eur Urol; 2019 Feb; 75(2):329-340. PubMed ID: 30344087
[TBL] [Abstract][Full Text] [Related]
15. Sildenafil treatment in vivo stimulates Leydig cell steroidogenesis via the cAMP/cGMP signaling pathway.
Andric SA; Janjic MM; Stojkov NJ; Kostic TS
Am J Physiol Endocrinol Metab; 2010 Oct; 299(4):E544-50. PubMed ID: 20663985
[TBL] [Abstract][Full Text] [Related]
16. Profibrotic role of myostatin in Peyronie's disease.
Cantini LP; Ferrini MG; Vernet D; Magee TR; Qian A; Gelfand RA; Rajfer J; Gonzalez-Cadavid NF
J Sex Med; 2008 Jul; 5(7):1607-22. PubMed ID: 18422491
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase.
Dunkern TR; Feurstein D; Rossi GA; Sabatini F; Hatzelmann A
Eur J Pharmacol; 2007 Oct; 572(1):12-22. PubMed ID: 17659276
[TBL] [Abstract][Full Text] [Related]
18. A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression.
Bivalacqua TJ; Diner EK; Novak TE; Vohra Y; Sikka SC; Champion HC; Kadowitz PJ; Hellstrom WJ
J Urol; 2000 Jun; 163(6):1992-8. PubMed ID: 10799245
[TBL] [Abstract][Full Text] [Related]
19. Ectopic expression of bovine type 5 phosphodiesterase confers a renal phenotype in Drosophila.
Broderick KE; Kean L; Dow JA; Pyne NJ; Davies SA
J Biol Chem; 2004 Feb; 279(9):8159-68. PubMed ID: 14662775
[TBL] [Abstract][Full Text] [Related]
20. The genetic inactivation of inducible nitric oxide synthase (iNOS) intensifies fibrosis and oxidative stress in the penile corpora cavernosa in type 1 diabetes.
Ferrini MG; Rivera S; Moon J; Vernet D; Rajfer J; Gonzalez-Cadavid NF
J Sex Med; 2010 Sep; 7(9):3033-44. PubMed ID: 20626593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
